Search Result

Isoforms Recommended:	ATR

Results for "

ATR

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ATM/ATR (41) Apoptosis (2) Autophagy (1) Bacterial (2) BCL6 (1) CDK (2) CMV (1) DNA-PK (1) DNA/RNA Synthesis (1) Histone Methyltransferase (1) HSV (1) Influenza Virus (1) MEK (1) mTOR (3) Nucleoside Antimetabolite/Analog (1) PI3K (1) PROTACs (2) Small Interfering RNA (siRNA) (3) STAT (1)
By Research Areas:	Cancer (47) Infection (2)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Targets Recommended: ATM/ATR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153462

ATR-IN-24

ATM/ATR Cancer

ATR-IN-24 (Compound 1) is a ATR inhibitor. ATR-IN-24 has anticancer activity .

ATR-IN-24	ATM/ATR	Cancer
ATR-IN-24 (Compound 1) is a *ATR* inhibitor. ATR-IN-24 has anticancer activity .

HY-144435

ATR-IN-11	ATM/ATR	Cancer
ATR-IN-11 (Compound Hit01) is a potent inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase. ATR kinase is a key regulating protein within the DNA damage response (DDR), responsible for sensing replication stress (RS). ATR-IN-11 is a promising lead compound for subsequent agent discovery targeting ATR kinase. ATR-IN-11 has the potential for the research of cancer disease .

HY-145450

ATR-IN-9	Others	Cancer
ATR-IN-9 is a potent inhibitor of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR) extracted from patent WO2020087170A1, compound 59, has an IC₅₀ of 10 nM .

HY-142924

ATR-IN-8	ATM/ATR	Cancer
ATR-IN-8 is a potent inhibitor of *ATR. ATR* is a key enzyme in the homologous recombination repair pathway and belongs to the PIKK family. ATR-IN-8 has the potential for the research of cancer diseases (extracted from patent WO2021143821A1, compound 3) .

HY-151915

ATR-IN-20	ATM/ATR mTOR	Cancer
ATR-IN-20 is a potent *ATR* (ATM/ATR) inhibitor with an IC₅₀ of 3 nM. ATR-IN-20 possess an inhibitory effect on mTOR (IC₅₀ of 18 nM) while displaying good selectivity against PI3Kα (100 nM), ATM (100 nM), and DNA-PK (662 nM). ATR-IN-20 exhibits excellent pharmacokinetic profile (F = 30%), and has anticancer effects .

HY-144436

ATR-IN-12	ATM/ATR	Cancer
ATR-IN-12 (Compound 5g) is a potent inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase with an IC₅₀ value of 0.007 μM. ATR-IN-12 displays good anti-tumor activity and significantly reduces the phosphorylation level of ATR and its downstream signaling protein. ATR-IN-12 is a promising lead compound for subsequent agent discovery targeting ATR kinase .

HY-147565

ATR-IN-13	ATM/ATR	Cancer
ATR-IN-13 (compound A9) is a potent *ATR* kinase inhibitor, with an IC₅₀ of 2 nM. ATR-IN-13 can be used for ATR kinase mediated diseases research, such as proliferative diseases and cancer .

HY-149952

ATR-IN-23	ATM/ATR	Cancer
ATR-IN-23 (Compound 34) is a potent and selective *ATR* inhibitor with an IC₅₀ of 1.5 nM. ATR-IN-23 has potent antiproliferative effects on LoVo cells and synthetic lethality on HT-29 cells, and can be used in the study of DNA damage response (DDR)-deficient cancers .

HY-147566

ATR-IN-14	ATM/ATR	Cancer
ATR-IN-14 (compound 1) is a potent *ATR* kinase inhibitor. ATR-IN-14 inhibits ATR signaling pathways downstream CHKI protein phosphorylation, with inhibition of 98.03% at 25 nM. ATR-IN-14 shows good anticancer activity in LoVo cells, with an IC₅₀ of 64 nM .

HY-142671

ATR-IN-5	ATM/ATR	Cancer
ATR-IN-5 is a potent inhibitor of *ATR. ATR* is a class of protein kinases involved in genome stability and DNA damage repair, and is a member of the PIKK family. ATR-IN-5 has the potential for the research of ATR kinase-mediated diseases such as proliferative diseases and cancer (extracted from patent CN112047938A, compound D24) .

HY-153729

ATR-IN-29

ATM/ATR Cancer

ATR-IN-29 is a potent and orally active ATR kinase inhibitor with an IC₅₀ value of 1 nM. ATR-IN-29 shows antiproliferative activity .

ATR-IN-29	ATM/ATR	Cancer
ATR-IN-29 is a potent and orally active ATR kinase inhibitor with an IC₅₀ value of 1 nM. ATR-IN-29 shows antiproliferative activity .

HY-153400

ATR-IN-22	ATM/ATR	Cancer
ATR-IN-22 (Compound 34) is an orally active *ATR* inhibitor. ATR-IN-22 inhibits MIAPaCa-2 proliferation (IC₅₀ <1 μM). ATR-IN-22 shows anti-tumor activity in colon cancer .

HY-142672

ATR-IN-6	ATM/ATR	Cancer
ATR-IN-6 is a potent inhibitor of *ATR. ATR* is a class of protein kinases involved in genome stability and DNA damage repair, and is a member of the PIKK family. ATR-IN-6 has the potential for the research of ATR kinase-mediated diseases such as proliferative diseases and cancer (extracted from patent WO2021233376A1, compound A22) .

HY-147568

ATR-IN-16

ATM/ATR Cancer

ATR-IN-16 (compound 46) is a potent ATR kinase inhibitor. ATR-IN-16 shows good anticancer activity in LoVo cells, with an IC₅₀ of 410 nM .
HY-147569

ATR-IN-17

ATM/ATR Cancer

ATR-IN-17 (compound 88) is a potent ATR kinase inhibitor. ATR-IN-17 shows good anticancer activity in LoVo cells, with an IC₅₀ of 1 nM .

ATR-IN-16	ATM/ATR	Cancer
ATR-IN-16 (compound 46) is a potent *ATR* kinase inhibitor. ATR-IN-16 shows good anticancer activity in LoVo cells, with an IC₅₀ of 410 nM .

ATR-IN-17	ATM/ATR	Cancer
ATR-IN-17 (compound 88) is a potent *ATR* kinase inhibitor. ATR-IN-17 shows good anticancer activity in LoVo cells, with an IC₅₀ of 1 nM .

HY-147570

ATR-IN-18	ATM/ATR	Cancer
ATR-IN-18 (compound 2) is an orally active and potent *ATR* kinase inhibitor, with an IC₅₀ of 0.69 nM. ATR-IN-18 shows antiproliferative activity in LoVo cells, with an IC₅₀ of 37.34 nM. ATR-IN-18 has anti-tumor activity .

HY-147190

ATR-IN-19

ATM/ATR Cancer

ATR-IN-19 (Compound 15 R-configure) is an ATR inhibitor .
HY-153393

ATR-IN-21

ATM/ATR Cancer

ATR-IN-21 (compound 60) is a potent ATR inhibitor with an IC₅₀ value of <1000 nM .

ATR-IN-19	ATM/ATR	Cancer
ATR-IN-19 (Compound 15 R-configure) is an *ATR* inhibitor .

ATR-IN-21	ATM/ATR	Cancer
ATR-IN-21 (compound 60) is a potent *ATR* inhibitor with an IC₅₀ value of <1000 nM .

HY-147567

ATR-IN-15	ATM/ATR DNA-PK PI3K	Cancer
ATR-IN-15 (compound 1) is an orally active and potent *ATR* kinase inhibitor, with an IC₅₀ of 8 nM. ATR-IN-15 also inhibits human colon tumor cells LoVo, DNA-PK and PI3K, with IC₅₀ values of 47, 663 and 5131 nM, respectively .

HY-144214

ATR-IN-10

ATM/ATR Cancer

ATR-IN-10 is a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase with an IC₅₀ value of 2.978 μM.

ATR-IN-10	ATM/ATR	Cancer
ATR-IN-10 is a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase with an IC₅₀ value of 2.978 μM.

HY-145312

ATR-IN-4	ATM/ATR	Cancer
ATR-IN-4 is a potent *ATR* (Ataxia telangiectasia mutated gene Rad 3-associated kinase) inhibitor. ATR-IN-4 inhibits growth of human prostate cancer cells DU145 and human lung cancer cells NCI-H460 with IC₅₀s of 130.9 nM and 41 .33 nM, respectively. (Patent CN112142744A, compound 13) .

HY-RS01245

ATR Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ATR Human Pre-designed siRNA Set A contains three designed siRNAs for ATR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ATR Human Pre-designed siRNA Set A ATR Human Pre-designed siRNA Set A

HY-RS01246

Atr Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Atr Mouse Pre-designed siRNA Set A contains three designed siRNAs for Atr gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Atr Mouse Pre-designed siRNA Set A Atr Mouse Pre-designed siRNA Set A

HY-RS01247

Atr Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Atr Rat Pre-designed siRNA Set A contains three designed siRNAs for Atr gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Atr Rat Pre-designed siRNA Set A Atr Rat Pre-designed siRNA Set A

HY-111451

Tuvusertib M1774; ATR inhibitor 1	ATM/ATR	Cancer
Tuvusertib (M1774; ATR inhibitor 1) is a selective and orally active *ATR* inhibitor extracted from patent WO2015187451A1, compound I-l, with a K_i value below 1 μΜ .

HY-136270

Gartisertib 2 Publications Verification VX-803; M4344; ATR inhibitor 2	ATM/ATR	Cancer
Gartisertib (VX-803) is an ATP-competitive, orally active, and selective *ATR* inhibitor, with a K_i of <150 pM. Gartisertib potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (Chk1) phosphorylation with an IC₅₀ of 8 nM. Antitumor activity .

HY-139609

Camonsertib RP-3500; ATR inhibitor 4	ATM/ATR mTOR	Cancer
Camonsertib (RP-3500) is an orally active, selective *ATR* kinase inhibitor (ATRi) with an IC₅₀ of 1.00 nM in biochemical assays. Camonsertib shows 30-fold selectivity for ATR over mTOR (IC₅₀=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. Camonsertib has potent antitumor activity .

HY-100399

Nevanimibe PD-132301; ATR-101
Nevanimibe (PD-132301) is an orally active and selective acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) inhibitor with an EC₅₀ of 9 nM. Nevanimibe inhibits ACAT2 with an EC₅₀ of 368 nM. Nevanimibe induces cell apoptosis and has the potential for adrenocortical cancer .

HY-100399A

Nevanimibe hydrochloride 2 Publications Verification PD-132301 hydrochloride; ATR101 hydrochloride
Nevanimibe hydrochloride (PD-132301 hydrochloride) is an orally active and selective acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) inhibitor with an EC₅₀ of 9 nM. Nevanimibe hydrochloride inhibits ACAT2 with an EC₅₀ of 368 nM. Nevanimibe hydrochloride induces cell apoptosis and has the potential for adrenocortical cancer .

HY-139558

Zapnometinib PD0184264; ATR-002	MEK Influenza Virus Bacterial	Infection Cancer
Zapnometinib (PD0184264), an active metabolite of CI-1040, is a MEK inhibitor, with an IC₅₀ of 5.7 nM. Zapnometinib exhibits antiviral activity against influenza virus and antibacterial activities .

HY-157764

*PROTAC ATR* degrader-1**	PROTACs ATM/ATR	Cancer
PROTAC ATR degrader-1 (compound ZS-7) is a potent PROTAC degrader of ataxia telangiectasia and Rad3-related (ATR), with DC₅₀ of 0.53 μM. PROTAC ATR degrader-1 plays an importnt role in cancer research .

HY-157767

Abd110	PROTACs ATM/ATR	Cancer
Abd110 (compound 42i) is a Lenalidomide-based *PROTAC ATR* kinase** degrader. Abd110 selectively decreases ATR and phospho-ATR without affecting related kinases ATM and DNA-PKcs .

HY-101566S

Elimusertib-d3 BAY 1895344-d₃	ATM/ATR	Cancer
Elimusertib-d3 (BAY 1895344-d3) is the deuterium labeled Elimusertib (BAY 1895344). Elimusertib is a potent, orally active and selective ATR inhibitor and has anti-tumor activity .

HY-13816

NU6027	CDK ATM/ATR	Cancer
NU6027 is a potent and ATP-competitive inhibitor of both CDK1 and CDK2, with K_is of 2.5 µM and 1.3 µM, respectively. NU6027 is also a potent inhibitor of *ATR* and enhances hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner .

HY-161138

WK369	BCL6 Apoptosis	Cancer
WK369 is a novel BCL6 small molecule inhibitor, which exhibits excellent anti-ovarian cancer bioactivity, induces cell cycle arrest and causes apoptosis. WK369 can directly bind to the BCL6-BTB domain and block the interaction between BCL6 and SMRT, leading to the reactivation of p53, ATR and CDKN1A .

HY-15520

CGK733

5 Publications Verification

ATM/ATR Cancer

CGK733 is a potent ATM/ATR inhibitor, used for the research of cancer.
HY-19323

Ceralasertib

25+ Cited Publications

AZD6738
ATM/ATR Cancer

Ceralasertib (AZD6738) is an orally active and bioavailable inhibitor of ATR kinase with an IC₅₀ of 1 nM.
HY-15521

ETP-46464

2 Publications Verification

mTOR ATM/ATR Cancer

ETP-46464 is an effective mTOR and ATR inhibitor with IC₅₀s of 0.6 and 14 nM, respectively.
HY-14731

VE-821

Maximum Cited Publications

36 Publications Verification

ATM/ATR Cancer

VE-821 is a potent ATP-competitive inhibitor of ATR with K_i/IC₅₀ of 13 nM/26 nM.

CGK733 5 Publications Verification	ATM/ATR	Cancer
CGK733 is a potent *ATM/ATR* inhibitor, used for the research of cancer.

Ceralasertib 25+ Cited Publications AZD6738	ATM/ATR	Cancer
Ceralasertib (AZD6738) is an orally active and bioavailable inhibitor of *ATR* kinase with an IC₅₀ of 1 nM.

ETP-46464 2 Publications Verification	mTOR ATM/ATR	Cancer
ETP-46464 is an effective mTOR and *ATR* inhibitor with IC₅₀s of 0.6 and 14 nM, respectively.

VE-821 Maximum Cited Publications 36 Publications Verification	ATM/ATR	Cancer
VE-821 is a potent ATP-competitive inhibitor of *ATR* with K_i/IC₅₀ of 13 nM/26 nM.

HY-13902

Berzosertib 10+ Cited Publications VE-822; VX-970	ATM/ATR	Cancer
Berzosertib (VE-822) is an *ATR* inhibitor with a K_i value of less than 0.2 nM. It also inhibits ATM with a K_i of 34 nM.

HY-15557

AZ20

5+ Cited Publications

ATM/ATR Cancer

AZ20 is a potent and selective inhibitor of ATR with an IC₅₀ of 5 nM, and has 8-fold selectivity against mTOR (IC₅₀=38 nM).

AZ20 5+ Cited Publications	ATM/ATR	Cancer
AZ20 is a potent and selective inhibitor of *ATR* with an IC₅₀ of 5 nM, and has 8-fold selectivity against mTOR (IC₅₀=38 nM).

HY-157941

ART0380	ATM/ATR	Cancer
ART0380 is a potent and selective *ATR* kinase inhibitor. ART0380 has selective antitumor activity that can be used for the research of Ataxia-Telangiectasia Mutated (ATM) aberrant cancers .

HY-101566A

Elimusertib hydrochloride 5+ Cited Publications BAY 1895344 hydrochloride	ATM/ATR	Cancer
Elimusertib (BAY 1895344) hydrochloride is a potent, orally active and selective *ATR* inhibitor with an IC₅₀ of 7 nM. Elimusertib hydrochloride has anti-tumor activity . Elimusertib hydrochloride can be used for the research of solid tumors and lymphomas .

HY-101566

Elimusertib 5+ Cited Publications BAY 1895344	ATM/ATR	Cancer
Elimusertib (BAY-1895344) is a potent, orally active and selective *ATR* inhibitor with an IC₅₀ of 7 nM. Elimusertib has anti-tumor activity . Elimusertib can be used for the research of solid tumors and lymphomas .

HY-144217

SKLB-197	ATM/ATR	Cancer
SKLB-197 showed an IC₅₀ value of 0.013 μM against ATR but very weak or no activity against other 402 protein kinases. It displayed potent antitumor activity against ATM-deficent tumors both in vitro and in vivo.

HY-12016

KU-55933 30+ Cited Publications	ATM/ATR Autophagy	Cancer
KU-55933 is a potent ATM inhibitor with an IC₅₀ and K_i of 12.9 and 2.2 nM, respectively, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

HY-112198

AZ31	ATM/ATR	Cancer
AZ31 is a a potent, highly selective, and orally active ATM inhibitor with an IC₅₀ of <1.2 nM for ATM enzyme, and an IC₅₀ of 46 nM for ATM in cell. AZ31 shows excellent selectivity over ATR (>500-fold) and excellent PIKK-family selectivity and pan-kinase selectivity. AZ31 is a potent radiosensitizer in vitro, it can be used for the research of cancer .

HY-19323A

(S)-Ceralasertib 1 Publications Verification (S)-AZD6738	ATM/ATR	Cancer
(S)-Ceralasertib ((S)-AZD6738) is extracted from patent WO2011154737A1, Compound II, exhibits an IC₅₀ of 2.578 nM . (S)-Ceralasertib is a potent and selective sulfoximine morpholinopyrimidine *ATR* inhibitor with excellent preclinical physicochemical and pharmacokinetic (PK) characteristics. (S)-Ceralasertib is developed improving aqueous solubility and eliminates CYP3A4 time-dependent inhibition .

HY-B0097

Floxuridine 3 Publications Verification 5-Fluorouracil 2'-deoxyriboside	Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Bacterial CMV HSV Apoptosis	Infection Cancer
Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis . Floxuridine has antiviral effects against HSV and CMV .

HY-16705

BRD4770 2 Publications Verification	Histone Methyltransferase	Cancer
BRD4770 is a histone methyltransferase G9a inhibitor. BRD4770 reduces di- and trimethylation of lysine 9 on histone H3 (H3K9) with an EC₅₀ of 5 µM, and has less or little effect toward H3K27me3, H3K36me3, H3K4me3, and H3K79me3. BRD4770 can activate the ataxia telangiectasia mutated (ATM) pathway and induce cell senescence .

Cat. No.	Product Name

HY-L173

Anti-Ovarian Cancer Compound Library

1867 Compounds compounds

Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer.

MCE designs a unique collection of 1867 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

HY-L004

Cell Cycle/DNA Damage Compound Library

1995 compounds

DNA is prone to numerous forms of damage that can injure cells and impair fitness. Cells have developed an array of mechanisms to repair these injuries. Proliferating cells are especially vulnerable to DNA damage due to the added demands of cellular growth and division. Cell cycle checkpoints represent integral components of DNA repair that coordinate cooperation between the machinery of the cell cycle and several biochemical pathways that respond to damage and restore DNA structure. By delaying progression through the cell cycle, checkpoints provide more time for repair before the critical phases of DNA replication, when the genome is replicated, and of mitosis, when the genome is segregated. Loss or attenuation of checkpoint function may increase spontaneous and induced gene mutations and chromosomal aberrations by reducing the efficiency of DNA repair.

MCE owns a unique collection of 1995 cell cycle/DNA damage-related compounds which can be used in the research of the same.

Cat. No.	Product Name	Type

HY-W011425A

NTPO trisodium Nitrilotris(methylenephosphonic acid), trisodium salt	Chelators
NTPO trisodium is a DNA damage inducer, causing genomic DNA damage and fragmentation, activating ATR-mediated cell cycle checkpoints. The DNA damaging effects of NTPO trisodium are abrogated by base excision repair (BER) but not nucleotide excision repair (NER) .

Species:	Human (2)
Tag:	Tag Free (1) Fc (1)
Source:	HEK293 (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P7521

	TEM8/ANTXR1 Protein, Human rHuAnthrax toxin receptor 1, His; ANTXR1; ATR; Anthrax toxin receptor 1	Human	HEK293
	TEM8/ANTXR1 Protein, Human is a 35-45 kDa Anthrax toxin receptor 1 protein expressed by HEK293 cells. Human Anthrax toxin receptor 1 is a type I membrane protein with an extracellular von Willebrand factor A domain that binds directly to protective antigen (PA). Human Anthrax toxin receptor 1 is also identified as the high-affinity cellular receptor for Seneca Valley Virus (SVV).

HY-P77226

	TEM8/ANTXR1 Protein, Human (HEK293, Fc) ANTXR1; ATR; Anthrax toxin receptor 1	Human	HEK293
	TEM8/ANTXR1 Protein, multifunctional in cell attachment and migration, interacts with extracellular matrix proteins and the actin cytoskeleton. This engagement mediates cell adhesion to type 1 collagen and gelatin, promoting actin cytoskeleton reorganization and cell spreading, crucial for cellular architecture and motility. TEM8/ANTXR1 also contributes to the angiogenic response in endothelial cells, emphasizing its role in vascular development. In microbial infections, it acts as a receptor for Bacillus anthracis protective antigen (PA), showcasing its dual function in cellular processes and host-pathogen interactions. TEM8/ANTXR1 Protein, Human (HEK293, Fc) is the recombinant human-derived TEM8/ANTXR1 protein, expressed by HEK293, with C-hFc labeled tag. The total length of TEM8/ANTXR1 Protein, Human (HEK293, Fc) is 321 a.a., with molecular weight of ~69 kDa.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks